This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Agilent Technologies

Profile

Agilent is a global leader in life science, diagnostics and analytical laboratory technologies.

Agilent Technologies Inc. is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help customers bring science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions.

As a CDMO, Agilent supports several commercial oligonucleotide therapeutics programs. In two cGMP facilities in Colorado, US, Agilent produces siRNA, antisense, aptamers, sgRNA, and other oligonucleotides. In 2023 Agilent announced a $725 million investment to expand manufacturing capacity that will allow us to take on more programs, increase batch sizes, and address our partners’ needs more quickly.

For the pharmaceutical and biopharmaceutical industries, Agilent provides end-to-end workflows from research and drug discovery, to development, manufacturing, and quality control. We strive to provide reliable answers to help overcome analytical challenges and optimize the productivity needs of labs. Complete solutions to help get products to market faster.

Leveraging more than 50 years of expertise, we create instruments, software, services and solutions that provide trusted answers to our customers’ most critical questions. We are passionate about helping them solve their most ambitious scientific challenges, increase laboratory performance, and advance the quality of life.

We're bringing you

  • Advancements in Analytical Tools for Future Cell and Gene Therapies: From Discovery and Analytical Oligonucleotide Methods to Commercial Production of Nucleic Acids for Clinical Trials and Therapeutics

    12:20